Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128, a Selective and Reversible P2Y12 Inhibitor, vs Clopidogrel, as a Novel Antiplatelet Therapy in Patients Undergoing Non-Urgent PCI

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128, a Selective and Reversible P2Y12 Inhibitor, vs Clopidogrel, as a Novel Antiplatelet Therapy in Patients Undergoing Non-Urgent PCI

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Clopidogrel (Primary) ; Elinogrel (Primary) ; Elinogrel (Primary)
  • Indications Embolism and thrombosis; Myocardial infarction
  • Focus Biomarker; Therapeutic Use
  • Acronyms INNOVATE-PCI
  • Sponsors Portola Pharmaceuticals

    • Most Recent Events

    • 02 Feb 2013 Planned number of patients changed from 650 to 800 as reported by European Clinical Trials Database.
    • 31 Aug 2010 Status changed from active, no longer recruiting to completed, according to the announcement of the presentation of results at ESC 2010 in a Portola Pharmaceuticals media release.
    • 29 Aug 2010 Results have been presented at SC Congress 2010: Annual Congress of the European Society of Cardiology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top